We are live on ! Find out more
VTVT icon

vTv Therapeutics
VTVT

14 hedge funds and large institutions have $789K invested in vTv Therapeutics in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

3.26% more ownership

Funds ownership: 0.11% → 3.37% (+3.3%)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

42% less funds holding

Funds holding: 24 → 14 (-10)

52% less capital invested

Capital invested by funds: $1.65M → $789K (-$858K)

90% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 10

Holders
14
Holders Change
-10
Holders Change %
-41.67%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
4
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$15K
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$8.16K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$393
4
Morgan Stanley
Morgan Stanley
New York
+$56

Top Sellers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
-$113K
2
State Street
State Street
Massachusetts
-$64.4K
3
Northern Trust
Northern Trust
Illinois
-$24.1K
4
TSS
Two Sigma Securities
New York
-$14.6K
5
SQA
Simon Quick Advisors
New Jersey
-$14.3K

VTVT Hedge Fund Activity: Q4 2023 in Review

14 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q4 2023, worth a combined $789K — down 52% from $1.65M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of VTVT and 1 opened new positions — a net loss of 9 holders — while 4 trimmed existing stakes and 3 added.

The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $15K. The largest seller was Geode Capital Management, exiting entirely with an estimated $113K sold.

  • 14 institutional investors held vTv Therapeutics (VTVT) as of Q4 2023, down from 24 in Q3 2023.
  • Funds reported $789K of vTv Therapeutics stock for Q4 2023, down 52% quarter-over-quarter.
  • 1 fund opened new vTv Therapeutics positions in Q4 2023 and 10 closed out, a net change of -9 holders.
  • The largest vTv Therapeutics buyer in Q4 2023 was Tower Research Capital (TRC), an estimated $15K added.
  • The largest vTv Therapeutics seller in Q4 2023 was Geode Capital Management, an estimated $113K sold.

Based on aggregated 13F filings for Q4 2023.